• Mehta headshotRank: Assistant Professor
    Website:http://www.uab.edu/medicine/hemonc/faculty/amitkumar-mehta-md
    Campus Address:
    NP 2556
    Mailing Address: 
    1720 2nd Avenue South, NP 2540
    Birmingham, AL 35294-3300
    Phone:  (205) 996-8400

    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.
     

    UAB Lymphoma Program Referral

    click here

    Lymphoma Clinic Referral

    click here

    Skin Lymphoma (CTCL) clinic referral

    click here

    Referral for Clinical trials in Lymphomas

    click here

    CAR-T therapy treatment referral

    click here

    Medical School:
    Medical College Baroda - India

    Internal Medicine Residency:
    Providence Hospital - George Washington University, Washington, D.C.

    Fellowships:
    Hematology/Oncology, University of Alabama at Birmingham

    Certifications:

    Board certified in Internal Medicine
    Board certified in Hematology
    Board certified in Medical Oncology

    Awards:
    American Society of Clinical Oncology
           Merit Award 2014 (Genitourinary)

    American Society of Clinical Oncology (ASCO)
        Conquer Cancer Foundation - Your Investigator Award 2014

    "I am currently assistant professor and associate scientist at the University of Alabama at Birmingham Comprehensive Cancer Center (UABCCC). I am board certified in Internal Medicine, Hematology and Oncology. My focus of interest is LYMPHOMA (Hodgkin lymphoma, Non Hodgkin lymphoma-T cell and B cell lymphomas). I specialize in treatments all types of lymphoma in my clinic. I am also involved in lymphoma related research, which includes genomic and proteomic (gene and protein related) studies in various kinds of lymphomas. As a clinical investigator I am also part of many clinical trials as principal investigator or sub investigator particularly in lymphomas. Many new promising targeted and immunologic treatments for lymphomas are being developed at UABCCC, which patients of lymphoma can benefit.

    My passion is to develop targeted and immunologic therapies in lymphomas with less toxicities and more effectiveness.

    My Research:


    Clinical:
    My research area involves:

    -Development of newer agents and combination of newer biologic agents in various kinds of lymphomas. I am principal investigator and sub investigator in many Phase I, II or III clinical trials. My passion is to develop biologic therapies with less toxicities and more effectiveness.

    -Survivorship research which involves well being of all lymphoma patients who have been exposed to chemotherapy, radiation therapy or had bone marrow transplant in past.

    -Development of blood test to diagnose and monitor lymphoma during and after treatment. This highly sensitive blood test identifies tumor related genes to monitor lymphoma. This test is still in developmental phase but may eliminate need for biopsies in future.

    Translational:
    -Lymphomas are biologically diverse tumors. Learning about their genetic make up and protein expression help us understand about their biology and develop new targeted and biological treatments. I collaborate with basic scientists and analyze lymphoma biopsies to understand biologic diversity and develop newer therapies.

    UAB Lymphoma program:
    UABCCC lymphoma program is comprehensive program involving specialists (medical oncology, surgical oncology, radiation oncology, Bone marrow transplant, survivorship and integrative medicine) and great nurses.

    Apart from lymphomas, I also see patients with blood cancers (malignant hematology) and blood related disorders (benign hematology).

    You can call my clinic (205-934-5077) or office (205-996-8400) for initial consultation, second opinions or clinical trials.

    Special Interests:

    • Lymphoma
    • Diffuse large B-cell
    • Follicular lymphoma
    • Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • T-Cell Lymphoma
    • Other B-Cell Lymphomas
    • Agressive Lymphomas
    • Any kind of skin lymphomas (Cutaneous T cell/B cell lymphomas)
    • Targeted Therapy
    • Clinical Trials
    • Disparity Research

    Access Dr. Mehta's profile on Linkedin and Doximity.

    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile


  • Rank: ProfessorRS14386 Andres Forero 2018 web 
    Director, Clinical Protocols & Data Management Share Facility
    Director, Breast Cancer Program

    Division:
    Hematology & Oncology

    Campus Address:
    NP 2510

    Mailing Address: 
    1720 2nd Avenue South, NP 2540
    Birmingham, AL 35294-3300

    Phone: 
    205-934-7167

    Email: aforero@uabmc.edu


    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Departmental Affiliation(s):
    Primary: Medicine

    Biosketch:

    A. PERSONAL STATEMENT

    I returned to the University of Alabama at Birmingham (UAB) Comprehensive Cancer Center (CCC) from Colombia in 2000 in order to pursue translational research with an emphasis on early clinical trials linked to laboratory observations in Breast Cancer and Lymphomas. Fortunately, upon my return I was able to continue working with my lifetime mentor, Dr. Albert F. LoBuglio, and received a K12 Individual Mentored Career Development Award sponsored by NCI, which provided me a major impetus to establishing my career as a clinical investigator with strong laboratory components to my research efforts. Additionally, I completed the K30 Clinical Research Training Program, a two-year course sponsored by the NCI that gave me the tools necessary to understand translational research. Over the past 10 years I have been the Director of the Clinical Protocols and Data Management Shared facility of the UAB CCC, I developed the first DSMP of the UAB CCC, I have led a large number of clinical trials (Investigator Initiated and Industry trials including studies holding INDs) with emphasis on early pilot, phase I and II studies, I have participated actively in the development and implementation of different projects through the Breast SPORE, and in my leadership role I led the team of investigators that developed the Susan G. Komen for the Cure Promise Grant which has 4 different projects (6.4 million dollars over 5 years). Over the last 8 years I have been the Principal Investigator of two translational research projects which have the potential to change and/or improve the standard of care management in breast cancer (Dual Pathway Target Inhibition in Breast cancer: ER and VEGF and Targeting Death Receptors for Treatment of Triple Negative Breast Cancer).

    B. POSITIONS

    1990-1991 Instructor, Physical Diagnosis Course, Department of Medicine, UAB

    1991-1997 Assistant Professor, Department of Medicine, Division of Hem/Onc, Javeriana University School of Medicine, Bogotá, Colombia

    1992-1995 Director of Clinical Oncology, Colombian NCI, Bogotá, Colombia

    1992-2000 Founding Member and Co-Director, Colombian Bone Marrow Transplant Program, Colombian NCI/Marly Clinic, Bogotá, Colombia

    1992-2000 Director, Division of Hem/Onc, Javeriana University Cancer Center, Bogotá, Colombia

    1998-2000 Associate Professor, Department of Medicine, Division of Hem/Onc, Javeriana University School of Medicine, Bogotá, Colombia

    2000-2001 Research Assistant Professor, Department of Medicine, Division of Hem/Onc; UAB

    2000-2006 Associate Scientist, UAB CCC

    2000-Present Director, Protocol/Data Management Shared Facility, UAB CCC

    2000-2004 Co-Chairman, Clinical Trials Review Committee, UAB CCC.

    2001-2006 Assistant Professor, Department of Medicine, Division of Hem/Onc; UAB

    2004-2010 Associate Scientist, Minority and Health Disparities Research Center, UAB

    2010-Present Scientist, Minority and Health Disparities Research Center, UAB

    2004-2005 Chairman, Clinical Trials Review Committee, UAB CCC

    2005-Present Co-Chairman, Clinical Trials Review Committee, UAB CCC

    2005-Present Chairman, Clinical Trials Monitoring Committee, UAB CCC

    2006-2010 Associate Professor, Department of Medicine, Division of Hem/Onc; UAB

    2006-Present Scientist, UAB CCC

    2010-Present Program Co-Leader, Experimental Therapeutics, UAB CCC

    2010-Present Professor, Department of Medicine, Division of Hem/Onc; UAB

    2012-Present The O'Neal-Sokol Breast Cancer Research Foundation of Alabama Endowed Professorship, UAB

    C. AWARDS and HONORS

    (1) Best Abstract in Clinical Research, Colombian Society of Hematology and Clinical Oncology Annual Meeting, Colombia, 1993; (2) Best Abstract in Clinical Cancer Research, Colombian Cancer Society Annual meeting, Colombia, 1997; (3) Henri Horoszowski Memorial Prize for the Best Orthopedic Presentation, International Society of Hemophilia, 1998; (4) Outstanding Teacher, University of Alabama at Birmingham, Division of Hematology/Oncology, Fellowship Training Program, 2003-2004; (5) Judge for the Oncology Competition; Southern Society for Clinical Investigation Oncology Young Investigator's Forum New Orleans, Louisiana; 2007; (6) Appointed as one of the Best Doctors in Alabama, 2007, 2008, 2009; (7) Elected to the Southern Society of Clinical Investigation, 2007; (8) Susan G. Komen for the Cure – 2008 Komen Promise Grant #1; 2008 Scientific Peer Review Meeting; Scientist Reviewer, Washington, March 2008; (9) Distinguished Board Member 2009 – The Breast Cancer Research Foundation of Alabama; (10) The Albert F. LoBuglio Distinguished Faculty Award 2009 (bestowed to a faculty member who has made distinguished contributions to the research activities of the Cancer Center); (11) Appointed as one of the Best Doctors in America and America's Top Doctors for Cancer, 2010; (12) Congressionally Directed Medical Research Program on Era of Hope Scholars in Breast Cancer 2010; Scientific Peer Review Meeting; Scientist Reviewer, Washington, April 2010.

    D. COMMITTEES

    1992-1997, Board Member, Colombian Research Group in Gastric Carcinoma; 1992-Present, Member, Medical Advisory Committee, Colombian Cancer Society; 1995-2000, Oncology Consultant and Investigator, Bristol Myers Squibb-Colombia; 1995-2000, Principal Investigator, Taxotere in the Treatment of Breast Carcinoma, National Cancer Institute; 1997-1999, Board Member, Colombian Cancer Society; 1998-2001, Board Member of GOL (Latin American Oncology Research Group); 2003-2009, Member, Non-Hodgkin's Lymphoma panel, National Comprehensive Cancer Network (NCCN) (National Level); 2003-2005, Member, Cancer Committee of UAB Health System; 2004-2009, Member, Hodgkin's Lymphoma panel, National Comprehensive Cancer Network (NCCN) (National Level); 2005-Present, Founding Member, The Translational Breast Cancer Research Consortium (National Level); 2006-Present, Member of the DSMB for the Phase II/III trial of Lumiliximab with or without FCR in patients with previously untreated CLL (International Level); 2007-Present, Founding member, Lymphoma Research Consortium (National Level; 2007-Present, Board Member, Breast Cancer Research Foundation of Alabama (State Level); 2008-Present, Member, Triple Negative Breast Cancer Working Group – Translational Breast Cancer Research Consortium (National Level); 2008 – 2010, Member, Operational Efficiency Working Group of the Clinical Trials Advisory Committee, National Cancer Institute (National Level); 2009-Present, Member, Breast Cancer Panel, National Comprehensive Cancer Network (NCCN) (National Level).

    E. SOCIETIES (Selected)

    American Society of Clinical Oncology, Member
    American Society of Hematology, Member
    Southern Society of Clinical Investigation, Member

    Clinical Interests
    Breast Cancer and Lymphomas
    Targeted Therapy

    Selected Publications
    1.Forero A, Meredith RF, Khazaeli MB, Carpenter DM, Shen S, Thornton J, Schlom J, LoBuglio AF: A novel monoclonal antibody design for radioimmunotherapy. Cancer Biother Radiopharm 18:751-759, 2003. Investigator Initiated Protocol.
    2.Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins J, Goris ML, Picozzi VJ, Axworthy DB, Breitz HB, Sims RB, Ghalie RG, Shen S, Meredith RF: Phase I trial of a novel anti-CD20 non-Hodgkin lymphoma. Blood 104:227-236, 2004. (Cover Page, July 1, 2004 Issue). Investigator Initiated Protocol.
    3.Forero-Torres A, Shen S, Breitz H, Sims RB, Axworthy DB, Khazaeli MB, Chen KH, Percent I, Besh S, LoBuglio AF, Meredith RF: Pretargeted® radioimmunotherapy (RIT) with a novel anti-TAG-72 fusion protein. Cancer Biother Radiopharm 20:379-390, 2005. Investigator Initiated Protocol.
    4.Forero A, Meredith RF, Khazaeli MB, Shen S, Grizzle WE, Carey D, Busby E, LoBuglio AF, Robert F: Phase I study of 90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration. Cancer Biother Radiopharm 20:467-478, 2005. Investigator Initiated Protocol.
    5.Triozzi P, Shah J, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle R, Conry M, LoBuglio AF, Forero A: Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity (ADCC). Cancer Biother Radiopharm 21; 6: 553-559, 2006. Investigator Initiated Protocol.
    6.Forero A, Shah J, Carlisle R, Triozzi P, LoBuglio A, Wang WQ, Fujimori M, Conry M: A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm 21; 6:561-568, 2006. Investigator Initiated Protocol.
    7.Forero-Torres A, Saleh MN: Bendamustine in non-Hodgkin lymphoma: the double-agent that came from the Cold War. Clinical Lymphoma Myeloma 8 (1): S13-7, 2007.
    8.Shah J, Wang W, Harrough D, Seville W, Meredith R, Shen S, Mueh J, Lister J, Jasthy S, Magas G, Mckay C, Krumdieck R, Tharp M, Winter C, Gregory M, Buchholz W, Awasthi S, Jacobs S, Cheng H, Egner J, LoBuglio AF, Forero A: Retreatment with Yttrium 90 Ibritumomab Tiuxetan in Patients with B-Cell Non Hodgkin's Lymphoma. Leukemia and Lymphoma 48 (9): 1736-1744, 2007.
    9.Meredith RF, Shen S, Forero-Torres A, LoBuglio AF: A method to correct for radioactivity in large vessels that overlap the spine in imaging-based marrow dosimetry of lumbar vertebrae. J Nucl Med 49:279-284, 2008. Investigator Initiated Protocol.
    10.Forero-Torres A, Leonard JP, Younes A, Rosenblatt JD, Brice P, Bartlett NL, Bosly A, Pinter-Brown L, Kennedy D, Sievers EL and Gopal AK: A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma. British Journal of Haematology 146: 171-179, 2009.
    11.Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, Harrop K, Whiting N, Drachman JG: Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma. Journal of Clinical Oncology 27 (26): 4371-4377, 2009.
    12.Shen S, Forero A, Meredith RF, Shah JJ, Knox SJ, Wiseman GA, Usrey ME, LoBuglio AF: Impact of Rituximab Treatment on 90Y-Ibritumomab Dosimetry for Patients with Non-Hodgkin's Lymphoma. Journal of Nuclear Medicine 2010; 51 (1): 150-157, 201. Investigator Initiated Protocol.
    13.Furman R, Forero A, Shustov A, Drachman J: A Phase I Study of Dacetuzumab (SGN-40, a HumanizedAnti-CD40 Monoclonal Antibody) in Patients with Chronic Lymphocytic Leukemia. Leukemia & Lymphoma 2010; 51 (2): 228-235.
    14.Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo F, Wojtowicz-Praga S, Percent I, Saleh M. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Cancer Biotherapy and Radiopharmaceuticals 2010; 25 (1): 13-19. (Investigator Initiated Protocol).
    15.Forero-Torres A, Saleh M, Galleshaw JA, Jones CF, Shah JJ, Percent IJ, Nabell LM, Carpenter JT, Falkson CI, Krontiras H, Urist MM, Bland KI, De Los Santos JF, Meredith R, Caterinicchia V, Bernreuter WK, O'Malley JP, Li Y, LoBuglio AF: A pilot trial of pre-operative (neoadjuvant) letrozole in combination with bevacizumab in post-menopausal women with newly diagnosed estrogen and/or progesterone receptor positive breast cancer. In Press 2010, Clinical Breast Cancer 2010; 10(4): 275-280. (Investigator Initiated Protocol).
    16.Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, and Forero-Torres A. Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas. N Engl J Med 2010; 363:1812-1821 (Senior Author).

    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to View UAB Health System Provider Profile
  • Rank:                 Saad Ayman 2016 web   
    Associate Professor of Medicine
    Blood and Marrow Transplantation and Cell Therapy Program

    Division:
    Hematology/Oncology

    Campus Address: 
    NP 2560

    Mailing Address:  
    1720 2nd Avenue South, NP 2560                             
    Birmingham, AL 35294-0006

    Phone: 
    (205) 934-1908

    Email:  
    asaad@uabmc.edu

    Website:
    https://www.uab.edu/medicine/bonemarrow/


    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.


    Medical School:
    Ain Shams Medical School, Cairo, Egypt

    Internal Medicine Residency:
    University of Maryland Medical System

    Fellowships:
    Hematology/Oncology, West Virginia University, Morgantown
    Research Fellowship, Wayne State University, Detroit, Michigan

    Certifications:
    Certified in Internal Medicine
    Certified in Hematology
    Certified in Medical Oncology

    Biosketch:
    Dr. Saad joined UAB in July 2012 as an Associate Professor of Medicine in the Division of Hematology/Oncology and as Scientist within the Experimental Therapeutics Program of the UAB Comprehensive Cancer Center. His research is focused on the use of hematopoietic stem cell transplantation to treat hematological diseases utilizing preparative and graft manipulation methods.He received his medical degree (MBBCh) from Ain Shams University in Cairo, Egypt in 1994. He finished his internship in 1996 and residency training in clinical oncology in 1999 in the same university, where he obtained Master Degree in Clinical Oncology in 1999 and subsequently appointed as a Faculty member in the same university.He joined Wayne State University in Detroit, Michigan in 2000 as a clinical research fellow. He finished internal medicine training in Maryland General Hospital/University of Maryland Medical System (2002-2005) and fellowship of Hematology and Oncology in West Virginia University (2005-2008). He joined the Medical College of Wisconsin as an assistant professor in 2008 until he moved to UAB in 2012.He is American Board certified in Internal Medicine, Medical Oncology and Hematology. He is also certified medical practitioner in Egypt.He authored several articles and book chapters.

    Honors
    - Merit Award of ASCO Foundation in 2007
    - Margaret J. Albrink Research Award of West Virginia University School of Medicine in 2007
    - Dennis M. Bush Excellence in Teaching Award of the Medical College of Wisconsin: 2009

    Clinical Interests
    The use of graft manipulation of hematopoietic stem cell transplantation as a model for immunotherapy to improve treatment outcome of hematological malignancies

    Society Memberships
    - American Society of Clinical Oncology (ASCO)
    - American Society of Hematology (ASH)
    - American Society for Blood and Marrow Transplantation (ASBMT)

    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile
  • Carla Falkson 2014 webRank:                  
    Professor

    Division:              
    Hematology & Oncology

    Campus Address:
    NP 2540

    Mailing Address:
    1720 2nd Avenue South, NP2540
    Birmingham, AL 35294-3300

    Phone: 
    (205) 975-2691




    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Biosketch:

    Dr. Falkson joined the Hematology/Oncology Faculty at UAB as a Professor of Medicine and Senior Scientist, Comprehensive Cancer Center in 2001. She is an alumnus of the MD Anderson Cancer Center.

    EDUCATION

    St. Mary's Diocesan School for Girls, Pretoria, South Africa: Joint Matriculation Board

    MB ChB (Baccalaureus in Medicine and Surgery) (USA MD equivalent) University of Pretoria, South Africa

    MMed(Int) (Masters in Internal Medicine) University of Pretoria, South Africa

    MD (Doctorate in Medicine) University of Pretoria, South Africa


    ACADEMIC APPOINTMENTS


    Feb 2001- present Professor of Medicine; Division Hematology/Oncology; University of Alabama at Birmingham, USA

    April 1998 – Feb 2001 Professor and Head (Chief Specialist), Dept Medical Oncology, University of Pretoria, So Africa

    April 1994- March 1998 Professor, Dept Medical Oncology, University of Pretoria, South Africa.

    Jan 1992- March 1998 Principal Specialist/Senior Lecturer, Dept Medical Oncology, University of Pretoria, So Africa

    Jun 1989‑Dec 1991 Specialist/Lecturer, Dept Medical Oncology, University of Pretoria, South Africa

    Jul 1987‑Jun 1989 Clinical Assistant/Lecturer, Dept Internal Medicine, University of Pretoria, South Africa

    July 1986‑June 1987 Clinical Fellow, Hematology Oncology, Division of Medicine, University of Texas System Cancer Center, MD Anderson Hospital and Tumor Institute, Houston, Texas, USA

    Jul 1987‑Jun 1989 Clinical Assistant/Lecturer, Dept Internal Medicine, University of Pretoria, South Africa

    Dec 1984‑Jun 1986 Clinical Assistant/Lecturer, Dept Internal Medicine, University of Pretoria, South Africa

    Nov 1983‑Nov 1984 Medical Officer/Lecturer, Dept Cancer Chemotherapy, University of Pretoria, South Africa

    Nov 1982‑Nov 1983 Intern, 1 Military Hospital, Pretoria, South Africa

    HOSPITAL AND OTHER (NON ACADEMIC) APPOINTMENTS

    Chairperson, Interdisciplinary Breast Clinic Steering Committee; UAB, USA (2001-2005)

    Chairperson for ECOG for NSABP-B 34 and S 0307. (2003-present)

    Bisphosphonate therapy in breast cancer and bone metastatses.
    Member : ECOG Breast Committee (1989- present) and Breast Core Committee (2001-present).

    Chairperson: Interdisciplinary Breast Cancer Working Group: University of Alabama at Birmingham, Comprehensive Cancer Center, USA (2001- 2005)

    Principal investigator for various clinical trials in breast cancer (1989-present)

    Member : CIRG, BIG (IBCSG), BREAST studies (1989- present)

    January 2005- present External Reviewer for Cancer Therapy Evaluation Program (CTEP) National Cancer Institute

    November 2004- present Member, Audit Committee, Eastern Cooperative Oncology Group

    1996 – 2003 – Member, Scientific Committee, 2nd, 3rd and 4th International Conference – Adjuvant Therapy of Malignant Melanoma, Royal Society of Medicine, London, UK

    November 2001- present Principal Investigator, Eastern Cooperative Oncology Group (ECOG) for the University of Alabama at Birmingham (UAB).

    September 2002-Nov 2006 Chairperson, Quality Assurance Committee, UAB Comprehensive Cancer Center

    2000-2002 – Member, International Organising Committee for the AORTC Conference 2001 (African Organisation for Research and Training in Cancer)

    1995-2001 – Member, Research Protocol and Ethics Committee, Pretoria Academic Hospital and University of Pretoria. Acting Chairman with needed.

    Feb 2001- January 2006 Chairperson of the Breast Cancer Interdisciplinary Working Group; UAB; Comprehensive Cancer Center

    Feb 2001- March 2003 Avon Breast Cancer Scholar; UAB Comprehensive Cancer Center

    Feb 2001- Sept 2003 Medical Director of the Breast Health Center; UAB; Comprehensive Cancer Center

    August 2001-Sept 2002 Co-Principal Investigator for NCCN for UAB

    1999-2001 – Member, Interim Provincial Pharmacy and Therapeutics Committee, Gauteng Department of Health

    March 17-19, 2000 – Chairperson, Organising Committee for SASMO/SASRO : Oncology 2000 Congress at Pretoria, South Africa

    1998-2001 – Member, Medical Research Council (MRC) of South Africa: Ethics Committee

    April 1997-June 1998 Chairman, Audit Committee, Eastern Cooperative Oncology Group

    1996-1997 – Member, Medical Ethics Education Subcommittee, Medical Association of South Africa

    April 1996-March 1997 Vice Chairman, Audit Committee, Eastern Cooperative Oncology Group

    May 1995-Feb 2001 Principal Investigator, Eastern Cooperative Oncology Group for the University of Pretoria.

    PROFESSIONAL/RESEARCH SOCIETIES

    1. American Society of Clinical Oncology (ASCO) (1990-present)

    2. American Association for Cancer Research (AACR) (1999-present)

    3. University of Texas M D Anderson Associates (1987-present)

    4. European Society for Medical Oncology (ESMO) (1991-present)

    5. Medical Association of the State of Alabama (2002- present)

    6. Jefferson County Medical Society (2002-present)

    7. South African Society of Medical Oncology (SASMO) (1989-present)

    8. Member :Third World Organization for Women in Science (TWOWS) (1995-present)

    9. Eastern Co-operative Oncology Group (ECOG) (1989-present)

    10. Breast Cancer International Research Group (BCIRG) (1998-present)

    11. BR.E.A.S.T. (Breast European Adjuvant Studies Team) (1998-present)

    12. International Breast Cancer Study Group (IBCSG) (1998-present)

    13. TBCRC (translational Breast Cancer Research Cosnsortium)

    Clinical Interests
    Carla I. Falkson has been actively involved in development and planning of trials, with an emphasis on clinical trials. Her research has been focused on developing innovative treatments for patients with cancer, as well as coordinating other aspects of cancer research. Her major interests are in the areas of breast cancer and melanoma. She is actively involved in planning ECOG's scientific research program. Examples of research include:

    Breast Cancer – designing adjuvant and metastatic trials, with emphasis on translational research and quality of life issues for women with breast cancer.

    Dr. Falkson is actively involved with development and planning of trials, with an emphasis on clinical trials in breast cancer. She is interested in fostering collaboration between groups and is Principal Investigator for UAB's Eastern Cooperative Oncology Group(ECOG) projects. She has been an active member of the ECOG Breast Committee since 1989 and a member of various other international breast cancer groups (for example BCIRG/CIRC).
    Examples of research include the use of bisphosphonates in breast cancer and chairing studies with these agents such as NSABP-B 34 and S 0307 for ECOG. The use of antiangiogenic agents in breast cancer and treatments for Her2-positive breast cancer are also areas of focus.

    Dr. Falkson has been actively involved with quality assurance in cancer research, including
    chairing UAB's Quality Assurance Committee and ECOG's Audit committee, and has been a
    member of the ECOG Publications Committee and Audit Committee since 1996.

    Other examples of research interests include: Bone metastatases in breast cancer; bisphosphonates as adjuvant therapy for breast cancer; clinical aspects of gamma delta T-cells in breast cancer; circulating serum-Her-2 neu in serum in breast cancer; Herceptin in breast cancer and tumor exosomal jak3BP-mediated immunosuppresion of NK cells in patients with breast cancer. Dr Falkson has also been involved with genetic studies (BRCA determination) in various South African populations. (Done in collaboration with the Department of Human Genetics, University of Pretoria) and co-chaired various breast cancer genetic studies in Pretoria (1995-2001) and co-chairman of various genetic studies eg BRCA1 & 2 determinations (see publications) and been a member of the ECOG Gene Therapy Committee (1997-2001).


    Selected Publications
    •Worthington J, Waterbor JW, Funkhouser E, Falkson C, Cofield S, Fouad M. Receipt of standard breast cancer treatment by African American and White women. Int J Med Sci. Jul 7;5(4):181-8, 2008.
    •Worthington J, Funkhouser E, Waterbor JW, Falkson C, Cofield S, Fouad M. Accuracy of registry breast cancer treatment data among cases treated in urban hospitals. Journal of Registry Management. 35 (2): 75-80 2008
    •Yu S, Liu C, Su K, Wang J, Liu Y, Zhang L, Li C, Cong Y, Kimberly R, Grizzle WE, Falkson C, Zhang HG. Tumor exosomes inhibit differentiation of bone marrow dendritic cells. J Immunol. Jun 1;178(11):6867-75. 2007.
    •Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Pawlicki M, Chan A, Smylie M, Liu M, Falkson C, Pinter T, Fornander T, Shiftan T, Valero V, Von Minckwitz G, Mackey J, Tabah-Fisch I, Buyse M, Lindsay MA, Riva A, Bee V, Pegram M, Press M, Crown J, on behalf of the BCIRG 006 Investigators. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (AC®T) with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab (AC®TH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study SABCS 2005 and 2006.
    •Biagi J, Herbert K, Smith C, Abdi E, Leahy M, Falkson C, Wolf M, Januszewicz H, Seymour J, Richards K, Matthews J, Dale B, Prince H A phase II study of dexamethasone, ifosfamide, cisplatin and etoposide (DICE) as salvage chemotherapy for patients with relapsed and refractory lymphoma. Leuk Lymphoma. 46(2):197-206. Feb 2005
    •Goedhals L, Falkson G, Smith BL, Falkson CI, Gasmi J, Lategan A, Burillon JP, His P. Vinorelbine and cisplatin in advanced squamous cell carcinoma of the cervix: the South African Experience. Anticancer Res. 25(3c):2489-92; May-Jun 2005
    •Wadler S, Levy D, Frederickson HL, Falkson CI, Wang Y, Weller E, Burk R, Ho G, Kadish AS; Eastern Cooperative Oncology Group. A phase II trial of interleukin-12 in patients with advanced cervical cancer: clinical and immunologic correlates. Eastern Cooperative Oncology Group study E1E96. Gynecol Oncol. 92(3):957-64 Mar 2004
    •Falkson Carla I .The Treatment of Metastatic Breast Cancer: Overview. Medical Professional Magazine Alabama Vol 1, No 1 2004
    •Edmonson JH, Ryan LM, Falkson CI, Hicks DG, Blum RH. Phase II Study of Ifosfamide + Doxorubicin in Patients with Advanced Synovial Sarcomas (E1793): A Trial of the Eastern Cooperative Oncology Group. Sarcoma 7:9-11, 2003
    •Retsas S , Falkson CI et al. Report on the 4th International Conference on the Adjuvant Therapy of Melanoma Held at the Royal College of Physicians, London, UK. March 15-16, 2002. Melanoma Research; 12 (3) A1-A4, 2002
    •Falkson CI, Lawson D, Ibrahim J, Kirkwood J, Cohen G, Whiteside T, Zarour H. A randomized, placebo-controlled phase III trial of yeast derived GM-CSF vs peptide vaccination versus GM-CSF plus peptide vaccination vs placebo in patients with "No Evidence of Disease" after complete surgical resection of "locally advanced" and/or Stage IV melanoma. An Eastern Co-operative Group trial. Melanoma Research, 12(3) A6, 2002
    •Schink, Weller, Harris, Cella, Gerstnet, Falkson C I, Wadler. Outpatient Taxol and Carboplatin for Suboptimally debulked Epithelial Carcinoma of the Ovary Results in Improved Quality of Life: An ECOG Phase II Study (E2E93). The Cancer Journal from Scientific American, Mar-Apr;7(2):155-164 , 2001
    •Nabholtz J, Falkson C, Campos D, Szanto J, Martin M, Chan S, Pienkowski T, Zaluski J, Pinter T, Krzakowski, Vorbiof D, Loenard R, Kennedy I, Azli N, Murawski M, Riva A, Pouillart P on behalf of TAX 306 study group. Docetaxel and doxorubicin (AT) compared to doxorubicin and cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial . J Clin Oncol. Mar 15;21(6):968-75, 2003.
    •Saphner T, Weller E A, Tormey D C, Pandya K J, Falkson C I, Stewart J, Robert N J. 21 day oral etoposide for metastatic breast cancer. A Phase II study and review of the literature. Am J Clin Oncol, 23: 258-262, 2000.
    •Mullin V, Cella D, Chang C-H, Eremenco S, Mertz M, Lent L, Falkson C I, Falkson G. Development of three African language translations of the FACT-G. Quality of Life Research, 9: 139-149, 2000.
    •Yawitch T M, Mertz M, Falkson C I, van Rensburg E J. Absence of commonly recurring BRCA1 mutations in black South African women with breast cancer. S A Med J, 90, 788 (2000) 2000
    •Simpson J F, Gray R, Dressler L G, Cobau C D, Falkson C I, Gillchrist K W, Pandya K J, Page D L, Robert N J. Prognostic value of histologic grade and proliferative activity in axillary node positive breast cancer: Results from the Eastern Cooperative Oncology Group (ECOG) companion study, E4189. J Clin Oncol, 18:2059-2069, 2000
    •Sparano JA, O'Neill A, Schaefer PL, Falkson CI, Wood WC. Phase II trial of doxorubicin and docetaxel plus granulocyte colony-stimulating factor in metastatic breast cancer: Eastern Cooperative Oncology Group Study E1196. J Clin Oncol. Jun;18(12): 2369-77. 2000

    Book Chapters

    •Falkson, CI, Breast Cancer. In: Oxmore House Publications, USA. 2003
    •Williams C and Falkson Carla. Adjuvant Therapy of Breast Cancer. In: Williams CKO, Olopade OI, Falkson CI (EDS): Breast Cancer in Women of African Descent. 2005.

    Abstracts
    •Falkson CI, Rossman J, Nabell L, et al. A phase II trial investigating if bevacizumab in combination with hormone therapy will reverse acquired estrogen independence in metastatic breast cancer patients. Abstract 1074, Proc ASCO 2008.
    •Elizabeth A. Kvale, Olivio Clay, Lesley A. Ross, Jocelyn McGee, Jerri Edwards, Carla Falkson, Karlene Ball. Cognitive and functional impairment in older cancer survivors. Abstract34;AACR 2007.
    • A. Forero-Torres, I. Percent, J. Galleshaw, L. Nabell, J. Carpenter, C. Falkson, C. Jones, H. Krontriras, J. De Los Santos, M. Saleh. Neo-adjuvant letrozole and bevacizumab. In Press ASCO 2008
    •S. A. McDaniel, H. Krontiras, J. T. Carpenter, L. M. Nabell, K. I. Bland, M. M. Urist, C. I. Falkson, A. Forero; Univ of Alabama At Birmingham, Birmingham, AL
    Safety and effectiveness of dose dense neoadjuvant chemotherapy in patients with stage II/IIIbreastcancer. Proc Amer Soc Clin Oncol 2006
    •Van Rensburg EJ, Yawitch TM, Schlebusch CM, Dorfling CM, Mertz MS and Falkson C I : BRCA1 Mutations in Black South African Breast Cancer Patients: Preliminary Results of a Population-based Study. Proc Am Assoc Cancer Res 42:661 (#3558) 2001
    •Falkson, C. I., Jooste, R., Falkson, H.C., Falkson, G., Rens, D., van Aarde, R. Eek, R.W. Cyclophosphamide, Methotrexate and Fluorouracil Plus or Minus Depo-Buserelin in Premenenopausal Women with Lymph Node Positive Breast Cancer. Proc Amer Soc Clin Oncol. (#1777), Vol 20 part 2 pg 7b, 2001
    •Rapoport, B.L., Mahomed, A. Uys, Falkson, C.I., Landers, G., Raats, J.,Significant Responces in Patients with Metastatic Breast Cancer Refractory to Anthracycline Therapy: Preliminary Results of a Phase I/II Clinical Trial of Cisplatin and Raltitrexed. Proc Amer Soc Clin Oncol. (#1927), Vol. 20 part 2 pg 45b, 2001
    •Raats, J., Rapoport, B.L., Mahomed, R., Uys,A., Eek, R., Slabber,C., Falkson, C.I., Landers, G., Moodley, D. A Phase I/II Clinical Trial of Cisplatin and Raltitrexed in newly Diagnosed Patients with Metastatic Carcinoma of Unknown Primary (CUP). Proc Amer Soc Clin Oncol. (#2292),Vol. 20 part 2 pg 135b, 2001
    •Flinn IW, Jemiai Y, Lee, S, Bennett, JM, Falkson, CI, Flynn, P, Pundaleeka, SK, Stadtmauer, E, Schnell, FM, Tallman, MS, Rowe, JM. Phase II Trial of Fludarabine and Cyclophosphamide (Flu/Cy) in Patients with Previously Untreated Chronic Lymphocytic Leukemia: An Eastern Cooperative Oncology Group Study. (E1997) Am Soc Hematology: (#2649) : 2001
    •Slabber C F, Falkson C I, Musi N N M, Burger W. A Phase II study of docetaxel in advanced, inoperable squamous carcinoma of the esophagus. Proc Amer Soc Clin Oncol. (#1151), pg 300a, 1999

    For an up to date list of publications, please click here: PubMed

    Click to View UAB Health System Provider Profile
  • Rank:   Salvador web
    Assistant Professor

    Campus Address:
    NP 2540

    Mailing Address: 
    1720 2nd Avenue South, NP2540
    Birmingham, AL 35294-3300

    Phone:  
    (205) 996-2329



    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Medical School:
    University of Texas Health Science Center, San Antonio

    Internal Medicine Residency:
    University of Texas Health Science Center, San Antonio

    Fellowship:
    Hematology/Oncology, University of Louisville, Kentucky

    Certifications:

    Board certified in Internal Medicine
    Board certified in Medical Oncology

    Dr. Salvador earned her MD and completed her internship, residency and a research fellowship at the University of Texas Health Science Center in San Antonio. She completed a fellowship in Oncology/Hematology at the University of Louisville where she is currently Assistant Professor in the Division of Medical Oncology/Hematology. Her primary clinical activities are in the medical oncology program for breast cancer. Her primary research interests are in preventive oncology and minority health related issues. 

    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile
  • Vaklavas Chris 2016 webRank:                  
    Assistant Professor

    Campus Address:
    NP 2540

    Mailing Address:
     
    1720 2nd Avenue South, NP2540
    Birmingham, AL 35294-3300

    Phone:  
    (205) 975-2914




    For an appointment, call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Medical School:
    Aristotelian University of Thessaloniki, Greece

    Internal Medicine Residency:
    University of Texas at Houston

    Fellowships:
    Univeristy of Texas, M.D. Anderson Cancer Center
    Hematology/Oncology, University of Alabama at Birmingham

    Certifications:

    Board certified in Internal Medicine
    Board certified in Hematology
    Board certified in Oncology

     
    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile
  • Das 2016Rank:
    Assistant Professor of Medicine at UAB
    Section Chief of Oncology at the Birmingham VA Medical Center

    Division:

    Hematology & Oncology

    Campus Address: NP 2502

    Mailing Address: 
    1720 2nd Avenue South, NP 2540
    Birmingham, AL 35294-3300



    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816

    Departmental Affiliation(s):
    Primary: Medicine

    Dr. Das also sees patients at the Birmingham Veteran Affairs Medical Center in the Hematology and Medical Oncology Clinic.  To make an appointment at the VA, please contact (205) 933-8101.

    Medical School:
    Grant Medical College, India
     
    Internal Medicine Residency:
    University of Alabama at Birmingham

    Fellowship:

    Hematology/Oncology, University of Alabama at Birmingham

    Certifications:
    Board certified in Internal Medicine
    Board certified in Hematology
    Board certified in Oncology


    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to View UAB Health System Provider Profile
  • Rank:                    Salzman Donna web
    Professor of Medicine                            
    Director of Education and Clinical Services, 
    Blood and Marrow Transplantation and Cell Therapy Program

    Website: https://www.uab.edu/medicine/bonemarrow/

    Division:              
    Hematology & Oncology

    Campus Address: NP 2570

    Mailing Address: 
    1720 2nd Avenue South, NP 2570
    Birmingham, AL 35294-0006

    Phone:  
    (205) 934-1908

    Email:  dsalzman@uabmc.edu

    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.


    Departmental Affiliation(s):
    Primary: Medicine

    Associate Chief of Staff
    University of Alabama at Birmingham                   January, 2008 - Present

    Inspector, Foundation for the Accreditation           2003 - Present
    of Cellular Therapy

    Director of Education and Clinical Services           July, 1996 - Present
    Bone Marrow Transplant Program
    University of Alabama at Birmingham

    Medical Director                                                 June,1996 - Present
    Bone Marrow Transplant Unit
    University of Alabama at Birmingham

    Education:
    Medical School:                                                 
    Louisiana State University School of Medicine, New Orleans, LA

    Internal Medicine Residency: 
                                                           
    Louisiana State University Affiliated Hospitals, New Orleans, LA

    Fellowships:                                                        
    Infectious Disease,
    Louisiana State University Medical Center, New Orleans, LA
                                                                                                                                                   
    Medical Hematology/Oncology, 
    University of Texas Health Science Center, San Antonio, TX
                                                                       

    Publications:
    See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile
  • Erica Stringer Reasor 2016 CopyRank:                    
    Assistant Professor

    Division:
                   
    Hematology & Oncology

    Campus Address:
    NP 2501

    Mailing Address:  
    1720 2nd Avenue South, NP 2540
    Birmingham, AL 35294-3300

    Phone:                   
    (205) 975-2816


    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.


    Departmental Affiliation(s):
    Primary: Medicine

    EDUCATION             
    Medical School
    University of South Alabama, Mobile, AL

    Internal Medicine Internship
    Tulane University

    Internal Medicine Residency
    Baptist Health System, Birmingham, AL

    Fellowships
    Hematology Oncology, The University of Chicago Medicine, Chicago, IL
    Clinical Pharmacology and Pharmacogenomics, The University of Chicago Medicine, Chicago, IL

    BOARD CERTIFICATIONS
    Internal Medicine
    Medical Oncology

    PROFESSIONAL SOCIETIES:
    American Society for Clinical Pharmacology and Therapeutics (ASCPT)
    American Society of Clinical Oncology (ASCO)
    American Association for Cancer Research (AACR)
    International Gynecologic Cancer Society (IGCS)
    American Society of Hematology (ASH)

    AWARDS
    2010 Resident Travel Award Recipient Recognized at American Society of
    Clinical Oncology
    2012 Young Doctor’s Summit Award Recipient Recognized at International Gynecologic Cancer Society
    2013 ASCO/AACR Methods in Clinical Cancer Research Scholarship Recipient
    2013 AACR Minority Scholar in Cancer Research Award
    2014 Conquer Cancer Foundation ASCO Young Investigator Award

    CLINICAL INTERESTS
    Breast Cancer
    Women’s Health
    Developmental Therapeutics
    Targeted Therapies

    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile
  • Rank:   Francisco_Robert_2013_small
    Professor 

    Division: 
    Hematology & Oncology

    Campus Address:
    WTI 210B

    Mailing Address: 
    1720 2nd Avenue South, NP2540
    Birmingham, AL 35294-3300

    Phone:  
    (205) 934-1394

    Email:   pacorobertuab@cs.com

    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Departmental Affiliation(s):
    Primary: Medicine

    1990-2016         Chief, Hematology-Oncology Section, Department of Veteran's Affairs Medical Center, Birmingham, AL

    1995-Present      Professor, Hematology-Oncology, University of Alabama at Birmingham Hospital

    EDUCATION:
    Medical Degree: 
                       
    University of Puerto Rico School of Medicine

    Internal Medicine Residency:  
    University of Puerto Rico School of Medicine

    Clinical Fellowship, Oncology:
    American Cancer Society, University of Alabama at Birmingham

    Cancer Research Fellowship:  
    U.S. Public Health, University of Alabama at Birmingham

    Certifications:
    Certified in Internal Medicine
    Certified in Hematology
    Certified in Medical Oncology

    PROFESSIONAL SOCIETIES:
    1977-Present American Society of Clinical Oncology
    1978-Present American Society of Hematology
    1985-Present American College of Physicians (Fellow)
    1993-Present International Association for the Study of Lung Cancer
    2000-Present American Association for Cancer Research

    MEMBERSHIPS: 
    Eastern Cooperative Oncology Group (ECOG)
    Radiation Therapy Oncology Group
    Medical Oncology Committee
    Lung Cancer Committee


    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile
  • Rank:Assistant Professor RS18319 Gabrielle Rocque web

    Division:
                  
    Hematology & Oncology

    Campus Address:
    WTI 240

    Mailing Address:  
    1720 2nd Avenue South, NP 2540
    Birmingham, AL 35294-3300

    Phone:                 
    (205) 975-2914


    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Departmental Affiliation(s):
    Primary: Medicine

    EDUCATION:
    Medical Degree: 
          
    MD     University of Wisconsin School of Medicine and Public Health, Madison, WI             

    Internal Medicine Residency:  
    University of Wisconsin, Madison

    Clinical Fellowship, Hematology/Oncology:
    University of Wisconsin, Madison

    Certifications:
    American Board of Internal Medicine
    Hematology
    Medical Oncology

    Awards:
    American Society Of Clinical Oncology (ASCO) Conquer Cancer Foundation- Young Investigator Award 2012 UAB Department of Medicine Walter B. Frommeyer, Jr., Fellowship in Investigative Medicine

    Membership in Professional Societies:
    American Society Of Clinical Oncology (ASCO)                                                   
                   Member of the ASCO Quality of Care Committee                                                             
                   Member of the ASCO Measures and ASCO Value Working Groups                                                                            
                   Chair of the ASCO Measures Working Group- 2015                                                                                

    American Association for Cancer Research                                                                        

    American Academy of Hospice and Palliative Medicine

    Biosketch:
    Dr. Gabrielle Rocque completed her medical doctorate at the University of Wisconsin in Madison in 2007, followed by residency training in Internal Medicine and fellowship in Hematology and Oncology also at the University of Wisconsin. She serves as the medical director for the UAB Health System Cancer Community Network and the network’s patient navigator program, Patient Care Connect. Dr. Rocque’s research interests include evaluating and improving the quality of healthcare delivery for cancer patients, with a focus on advanced breast cancer and provision of supportive care services to patients.

    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile
  • Williams Grant 2016 smallRank:                  
    Assistant Professor
    The Institute for Cancer Outcomes and Survivorship

    Campus Address:
    Lowder Building, Room 500

    Mailing Address: 
    1600 7th Avenue South, Lowder 500
    Birmingham, AL 35294

    Clinical Office Phone:(205) 975-2914
    Research Office Phone:
      (205) 638-2120


    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.


    Medical School:
    Drexel University College of Medicine, Philadelphia, PA

    Internal Medicine Residency:
    The University of North Carolina School of Medicine, Chapel Hill, NC

    Fellowships:
    2013 - 2015 The University of North Carolina School of Medicine, Chapel Hill, NC
    Translational and Clinical Research Curriculum, NC TraCS Institute
    2012 - 2015 The University of North Carolina School of Medicine, Chapel Hill, NC
    Fellowship in Medical Oncology, Research Track
    2011 - 2012 The University of North Carolina School of Medicine, Chapel Hill, NC
    Fellowship in Geriatric Medicine

    Certifications:

    Board certified in Internal Medicine
    Board certified in Geriatric Medicine
    Board certified in Medical Oncology


    PROFESSIONAL MEMBERSHIPS
    2015 - present International Society of Geriatric Oncology (SIOG)
    2013 - present American Society of Hematology (ASH)
    2013 - present North Carolina Oncology Association (NCOA)
    2012 - present American Society of Clinical Oncology (ASCO)
    2011 - present American Geriatric Society (AGS)

    NATIONAL PROFESSIONAL ORGANIZATIONS
    2015 - present Alliance for Clinical Trials in Oncology
    2014 - present Cancer Aging Research Group (CARG)

    Awards:
    2015 - 2016 Paul Calabresi Career Development Award for Clinical Oncology (K12)
    2015 U13 Conference Young Investigator Travel Grant Award
    2015 Cancer Outcomes Research Program Travel Award
    2014 - 2015 John A. Hartford Foundation Center of Excellence in Geriatric Medicine Scholar
    2013 Selected Participant to 12th Annual Southeastern Fellows Research Skills Retreat
    2011 - 2014 Reynolds Specialty Faculty Scholar, Donald W. Reynolds Foundation
    2011 The James A. Bryan Award for Excellence in Outpatient Internal Medicine
    2009 The Joseph Langbord Memorial Prize for Humanitarianism in Medicine
    2006 - 2009 Joe Mansfield Scholarship
    2006 - 2009 Endowed School of Medicine Scholarship
    2005 Cum Laude, Tulane University

    Research Interests:
    As both a Geriatrician and Oncologist, Dr. Williams’ research is focused on refining treatment selection and improving the outcomes of older adults with cancer. His research involves the use of geriatric assessment and novel biomarkers, such molecular markers of agingand body composition, to better evaluate functional age and developing interventional clinical trials to improve the tolerance and outcomes of older adults undergoing cancer treatment.



    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to View UAB Health System Provider Profile


  • Godby_2011_webRank:
    Assistant Professor
    Inpatient Medical Director of Oncology

    Division:
    Hematology & Oncology

    Website:
    https://www.uabmedicine.org/patient-care/conditions/multiple-myeloma

    Campus Address:
    NP 2572

    Mailing Address:
    1720 2nd Avenue South, NP 2540
    Birmingham, AL 35294-3300
     
    Phone: (205) 975-3409


    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Departmental Affiliation(s):
    Primary: Medicine

    Biosketch:
    Dr. Godby joined the faculty at the University of Alabama at Birmingham as Assistant Professor of Hematology and Oncology in July 2011.

    She sees patients at The Kirklin Clinic and at UAB's Acton Road location.

    Medical School:
    Mercer University School of Medicine, Macon, GA

    Internal Medicine Residency:
    University of Alabama at Birmingham, Birmingham, AL

    Fellowship:
    Hematology/Oncology, University of Alabama at Birmingham

    Certifications:
    Board certified in Internal Medicine
    Board certified in Hematology
    Board certified in Oncology

    Society Memberships:

    2001-present: American Medical Association

    2009-present: American Society of Clinical Oncology

    2009-present: American Society of Hematology

    Research Description
    I, along with multiple myeloma colleagues, established an interdisciplinary myeloma clinic in March 2013, which is the first clinic in Alabama dedicated solely to plasma cell malignancies. I have also represented UAB on the NCCN guidelines panel for multiple myeloma and have been asked to give UAB’s best of ASCO/ASH 2013 presentations focusing on the most recent developments in myeloma. My current goals include opening clinical trials for the relapsed/refractory myeloma patient population and to continue to serve the multiple myeloma patient population.

    Click to View UAB Health System Provider Profile

  • Rank:
      Assistant Lakshmin Nandagopal, MDProfessor of Medicine
     
    Division:              
    Hematology & Oncology

    Campus Address:
    NP 2504

    Mailing Address: 
    1720 2nd Avenue South, NP2540
    Birmingham, AL 35294-3300



    For an appointment, call (205) 934-9999 or toll free 1 (800) UAB-8816.


    Departmental Affiliation(s):
    Primary: Medicine

    EDUCATION
    Medical School:
    Thoothukudi Medical College, India

    Internal Medicine Residency:
    Wayne State University/Detroit Medical Center

    Fellowship:
    Hematolgy/Ocology, University of Alabama at Birmingham

    Certifications:
    Board certified in Internal Medicine

    ACADEMIC APPOINTMENTS
    7/18-present Assistant Professor of Medicine, UAB



    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to View UAB Health System Provider Profile

  • Rank:
                        Lisle Nabell, MD
    Professor of Medicine
    Director, Hem/Onc Fellowship Program
    Medical Director, Hem/Onc Clinics, TKC & Acton Road
     
    Division:              
    Hematology & Oncology

    Campus Address:
    NP 2566

    Mailing Address: 
    1720 2nd Avenue South, NP2540
    Birmingham, AL 35294-3300

    Phone:   (205) 934-3061

    Email:    lnabell@uabmc.edu

    For an appointment, call (205) 934-9999 or toll free 1 (800) UAB-8816.


    Departmental Affiliation(s):
    Primary: Medicine

    EDUCATION
    Medical School:
    University of North Carolina, Chapel Hill

    Internal Medicine Residency:
    University of Alabama at Birmingham

    Fellowship:
    University of Alabama at Birmingham

    Certifications:
    Board certified in Medical Oncology


    ACADEMIC APPOINTMENTS
    9/11-present Professor of Medicine
    9/03-9/11 Associate Professor of Medicine
    10/1995-9/03 Assistant Professor of Medicine University of Alabama Birmingham
    7/1993-10/95 Associate Faculty/Instructor University of Alabama Birmingham

    AWARDS AND HONORS
    1978-1982 Duke University's Dean's List
    1980-1981 Duke University Class Honors
    1982 Duke University Cum Laude
    1997 American Cancer Career Development Award
    2000 Cobbs/Rutsky Award for Clinical Excellence
    2001 Cobbs/Rutsky Award for Clinical Excellence
    2002 Cobbs/Rutsky Award for Clinical Excellence
    2002 Hematology/Oncology Fellow Award for Outstanding Teacher
    2002 Department of Medicine Outstanding Division Teacher
    2003 Cobbs/Rutsky Award for Clinical Excellence
    2004 Cobbs/Rutsky Award for Clinical Excellence
    2004 Department of Medicine Outstanding Division Teacher
    2005 Department of Medicine Outstanding Division Teacher
    2006 Department of Medicine Outstanding Division Teacher
    2007 Department of Medicine Outstanding Division Teacher
    2007 Hematology/Oncology Fellow Award for Outstanding Teacher
    2008 Department of Medicine Outstanding Division Teacher
    2009 Department of Medicine Outstanding Division Teacher

    PROFESSIONAL SOCIETIES
    American Society of Clinical Oncology 1997-current
    Southern Medical Association 1999-current
    Eastern Cooperative Oncology Group 2001-current

    COMMITTEE MEMBERSHIP
    Women's Task Force Committee in Medicine '97-current
    Head & Neck Working Group '97-current
    Breast Cancer Working Group '98-current
    Alabama Cancer Congress Head and Neck Committee '00-current
    Intern Selection Committee '01-current
    Pharmacy and Therapeutics Committee FY '96-'99
    Hematology/Oncology Clinical Practice Committee '97-'00
    UAB Clinical Counsel '99-'01

    UNIVERSITY ACTIVITIES
    Acting Director, Division of Hematology/Oncology 11/04-8/2008
    Reviewer, Protective Life Clinical Initiative 2004-current
    Medical Director TKC Heme/Onc Clinical Activities 1997-current
    Department of Medicine Clinical Practice Committee 1999-current
    The Kirklin Clinic Clinical Practice Committee 1999-current
    UAB Institutional Review Board Alternate 1999-current
    Medical Director Hematology/Oncology 1997-2000
    Fellowship Program Director Div of Hem/Onc 8/08-current

    EDITORIAL BOARD MEMBERSHIP
    National Comprehensive Cancer Network Breast Cancer Committee '98-current
    National Comprehensive Cancer Network Clinical Genetics Committee '98-'08
    National Comprehensive Cancer Network Outcomes Committee '98-'00

    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to View UAB Health System Provider Profile
  • RS20930 Lorena de Idiaquez Bakula Vert lpr 2018Rank:
    Assistant Professor 

    Division:
    Hematology & Oncology

    Campus Address:
    NP 2505

    Mailing Address: 
    1720 2nd Avenue South, NP 2540
    Birmingham, AL 35294-3300

    Phone: (205) 996-6074



    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Departmental Affiliation(s):
    Primary: Medicine

    Dr. de Idiaquez also sees patients at the Birmingham Veteran Affairs Medical Center as an Attending Physician in the Hematology and Medical Oncology Clinic.  To make an appointment at the VA, please contact (205) 933-8101.


    Medical School:
    Universidad Peruana Cayetano Heredia (UPCH), Lima, Peru
     
    Internal Medicine Residency:
    University of Alabama at Birmingham

    Fellowship:

    Hematology/Oncology, University of Alabama at Birmingham

    Certifications:
    Board certified in Internal Medicine
    Board certified in Hematology
    Board certified in Oncology


    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to View UAB Health System Provider Profile
  • RS17381 Luciano Costa 2017 webRank:  
    Associate Professor of Medicine
    Blood and Marrow Transplantation and Cell Therapy Program

    Website:
    https://www.uab.edu/medicine/bonemarrow/

    Division:  
    Hematology & Oncology

    Campus Address:
    NP 2554

    Mailing Address: 
    1720 2nd Avenue South, NP 2554
    Birmingham, AL 35294-3300

    Phone:  (205) 934-1908

    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Departmental Affiliation(s):
    Primary: Medicine

    EDUCATION:
    Medical Degree: 
                       
    MD     Universidade de Sao Paulo, Brazil
    PhD    Universidade de Sao Paulo, Brazil

    POSTDOCTORAL TRAINING:
    Residency in Internal Medicine         Universidade de Sao Paulo
    Fellowship in Hem/Onc                     University of Colorado
    Fellowship in BMT                             Mayo Clinic
    Residency in IM                              Wayne State University

    PROFESSIONAL SOCIETIES:
    American Society of Hematology
    American Society for Blood and Marrow Transplantation
    Center for International Blood and Marrow Transplant Research
    Southwest Oncology Group
    Foundation for Accreditation of Cellular Therapy (FACT)
          -Inspector. 2013-

    MAJOR RESEARCH INTERESTS:
    Strategies for hematopoietic stem cell transplantation in chronic lymphoproliferative disorders. Toxicity of hematopoietic stem cell transplantation. Population outcomes of hematologic malignancies.

    Publications:See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to View UAB Health System Provider Profile
  • Saleh Mansoor 2016 webRank: 
    Professor of Medicine
    Director, Phase I Program of the Comprehensive Cancer Center
    Director, Phase I Clinical Program within the Clinical Center for Translational Science
    Medical Director, UAB Clinical Trials Office

    Division: 
    Hematology & Oncology

    Campus Address:
    WTI 260J

    Mailing Address: 
    1720 2nd Avenue South, WTI 260
    Birmingham, AL 35294-3300

    Phone:
    (205) 934-2248 or (205) 996-HOPE (4673)

    Email:
    mns@uab.edu


    For an appointment, call(205) 934-9999 or toll free 1 (800) UAB-8816.

    Departmental Affiliation(s):
    Primary: Medicine

    Medical School:  University of Heidelberg, Heidelberg, West Germany

    Internal Medicine Residency:  Henry Ford Hospital, Detroit, Michigan

    Fellowship:  Clinical/Research Fellow, Division of Hematology/Oncology, University of Alabama at Birmingham

    Certifications:  American Board of Internal Medicince, Certified in Hematology and Medical Oncology

    Clinical Interests: Clinical Trials

    Personal Statement
    My hematology/oncology fellowship training included laboratory investigation in the immune mediated platelet destruction (ITP), as well as, the generation of human monoclonal auto-antibodies from splenic B-cells derived from ITP patients. My NIH funded RO1 grant contributed to my clinical/research interest in the biology and treatment of ITP. I was one of the lead USA investigators on the pivotal trial leading to the FDA approval of the recombinant TPO receptor agonist elthrombopag for the treatment of ITP.

    My translational research training included studying monoclonal antibodies against cancer associated target antigens, and I have been the PI or co-PI of a number of breakthrough, first-in-human, clinical trials of mouse, chimeric and humanized anti-tumor monoclonal antibodies conducted at UAB. My laboratory conducted the initial study demonstrating the synergistic role of anti-EGFR MoAb and radiation therapy, and these observations led to the pivotal RTOG trial and FDA approval of Erbitux/RT for the treatment of locally advanced Head/Neck cancer.
                                 
    As part of my translational research laboratory investigations, I developed and subsequently patented the first mirror-image anti-Id vaccine that mimics the tumor associated GD2 ganglioside.

    Over the past 25 years I have been involved in the development, conduct and oversight of clinical trials involving monoclonal antibodies, cytotoxic chemotherapies vaccines, inhibitory small molecules and novel check-point inhibitors and immuno-oncology therapeutics.

    During this time I have served as Chairman of UAB Cancer Center’s Protocol Review Committee, a member of the Gene Therapy Panel, and senior scientist and translational clinician at the Cancer Center.

    Following my academic career, I spent 15 years in community oncology practice and established a Department of Defense (DOD)-funded Clinical Trials Program, including a first-in-human phase I program, in a community setting.

    I recently returned to UAB to head the Phase I, first-in-human drug development program and serve as the Medical Director of the UAB Clinical Trials Office. I am the co-lead investigator (together with Dr. I. Chaudry) of a DOD contract for the conduct of a Phase 1 first-in-human study of EE3SO4, a synthetic estrogen that in animal model has demonstrated unique properties of combating hemorrhagic shock, an application that could revolutionize how we treat various forms of acute hemorrage in patients.

    In addition to my interest in clinical and translational research, I have been an ardent promoter of cancer awareness in the LMIC and training clinicians in the early detection and treatment of common cancers.

    1. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.
    2. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF. J Immunol. 1993 Sep 15;151(6):3390-8.
    3. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ. Cancer Biother Radiopharm. 1999 Dec;14(6):451-63
    4. Buribekova R, Shukurbekova I, Ilnazarova S, Jamshevov N, Sadonshoeva G, Sayani S, Saleh, M: Promoting Clinical Breast Evaluations in a Lower Middle Income Country Setting - An Approach Towards Achieving a Sustainable Breast Health Program. J Glob Oncol 4: 1-8, 2018

     Positions and Honors

    1985-1986          Instructor in Medicine, Department of Internal Medicine, Division of Hematology/Oncology, University of Alabama at Birmingham and Veterans Administration Hospital, Birmingham, AL
    1985-1992          Associate Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham
    1988-1992          Assistant Professor of Medicine, Division of Hematology/ Oncology, University of Alabama at Birmingham
    1989-1999          Director, Immune Cytopenia Laboratory, University of Alabama at Birmingham
    1992-1998          Associate Professor of Medicine, Division of Hematology/ Oncology; Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham
    1993-1998          Associate Professor of Pathology, Division of Laboratory Medicine, University of Alabama at Birmingham
    1995-1999          Associate Director for Clinical Research, Comprehensive Cancer Center, University of Alabama at Birmingham
    1995-1999          Chairman, Clinical Trials Review Committee, Comprehensive Cancer Center, University of Alabama at Birmingham
    1977-Present     Scientist, Center for AIDS Research, University of Alabama at Birmingham
    1997-1999          Director for Clinical Research, Division of Hematology/Oncology, University of Alabama at Birmingham
    1998-Present     Professor of Medicine, Division of Hematology/Oncology, Scientist, Comprehensive Cancer Center, University of Alabama at Birmingham Professor of Pathology, Department of Pathology, University of Alabama at Birmingham
    1999-Present     Associate Director for Clinical Trials Network, University of Alabama at Birmingham, Comprehensive Cancer Center
    1999-2015          Staff Member – Georgia Cancer Specialists, Atlanta, GA
    1999-2015          Director for Research Development, Georgia Cancer Specialists, Atlanta, GA
    2004-Present     Chairman, Clinical Trials Review Committee, Comprehensive Cancer Center, University of Alabama at Birmingham
    2013-2015          Director for Clinical Research – UAB Cancer Community Network
    2014-Present     Member – Research Advisory Committee, Northside Hospital Cancer Institute
    2015-Present     Professor of Medicine, Division of Hematology/Oncology Senior Scientist, UAB Comprehensive Cancer Center, Medical Director, UAB Clinical Trials Office, Director, UAB Phase I Program, Medical Director, UAB Clinical Trials Office
    2015-Present  Medical Director for the UAB Clinical Trials Office
    2018-Present  Professor, Academic Support Department, University of Alabama at Birmingham, School of Nursing   

    Visiting Professorship
    1988                            Visiting Professor, Aga Khan University Hospital and Medical Center, Karachi, Pakistan
    2011                            Visiting lecturer, Aga Khan University Nairobi, Kenya2012-Present  Visiting Professor, Aga Khan University Nairobi, Kenya

    Honors

    1977                            Gifted Scholar Scholarship Award, Friedricht Ebert Foundation, West Germany
    1980                            University of Heidelberg Medical Doctorate - Magna Cum Laude
    1986-1989                   Leukemia Society of America Fellowship Award
    1986-1989                   Merit Award - Veteran’s Administration Hospital
    1995                            Aga Khan Health Board Award for Excellence in Academic Medicine

    Contributions to Science


    1. My early work addressed the role of antibody dependent cellular cytotoxicity in immune platelet destruction (ITP). I contributed to the description of the role of platelet associated IgG in immune mediated platelet destruction and 2 decades later, as one of the lead clinical investigators, conducted clinical trials that led to the FDA approval of TPO-receptor agonist elthrombopag in the treatment if ITP.
      1. Monocyte-platelet interaction in immune and nonimmune thrombocytopenia. Saleh MN, Moore DL, Lee JY, LoBuglio AF.Blood. 1989 Sep;74(4):1328-31.
      2. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A; EXTEND Study Group. Blood. 2013 Jan 17;121(3):537-45. doi: 10.1182/blood-2012-04-425512. Epub 2012 Nov 20.
      3. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. N Engl J Med. 2007 Nov 29;357(22):2237-47.
    1. My laboratory was one of the first that described the synergistic effect of radiation therapy and anti-EGFR MoAb in the treatment of EGFR-expressing tumor cells in vitro. This laboratory finding led to the first in human clinical trial of the MoAb anti-EGFR (Cetuximab) plus radiation therapy for the treatment of locally advanced squamous carcinoma of the head/neck. The positive results from this phase I clinical trial ultimately led to a pivotal randomized trial through the RTOG leading to the FDA approval of Cetuximab combined with radiation therapy in the treatment of locally advanced or recurrent squam. cell carcinoma of the head/neck
      1. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ. Cancer Biother Radiopharm. 1999 Dec;14(6):451-63
      2. Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW
    1. In 2002 I moved from UABCCC to establish a DOD-funded clinical trials program at the community level as a partnership between UABCCC and Georgia Cancer Specialists (GCS), one of the 5 largest community oncology practices in the USA. In the 15yr I spent at GCS, I continue to play an active academic role at UABCCC while establishing a robust clinical trials program, including first in human trials, at GCS. During this time I was PI of numerous clinical trials, including pivotal studies that led to the FDA approval of a number of novel molecules for the treatment of cancer.
      1. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. Bussel JB, Cheng G, Saleh MN, Psaila B, Kovaleva L, Meddeb B, Kloczko J, Hassani H, Mayer B, Stone NL, Arning M, Provan D, Jenkins JM. N Engl J Med. 2007 Nov 29;357(22):2237-47.
      2. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, Harris M, Reni M, Dowden S, Laheru D, Bahary N, Ramanathan RK, Tabernero J, Hidalgo M, Goldstein D, Van Cutsem E, Wei X, Iglesias J, Renschler MF. N Engl J Med. 2013 Oct 31;369(18):1691-703. doi: 10.1056/NEJMoa1304369. Epub 2013 Oct 16.
      3. Abiraterone and increased survival in metastatic prostate cancer. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI; COU-AA-301 Investigators
    1. My clinical investigator training under the mentorship of Al LoBuglio contributed to my dedication to early phase, first-in-human, clinical trials, resulting in my recruitment back to UABCCC to direct the UAB and Cancer Center’s Early Drug Development Phase 1 Program.
      1. Phase I trial of weekly tigatuzumab, an agonistic humanized monoclonal antibody targeting death receptor 5 (DR5). Forero-Torres A, Shah J, Wood T, Posey J, Carlisle R, Copigneaux C, Luo FR, Wojtowicz-Praga S, Percent I, Saleh M. Cancer Biother Radiopharm. 2010 Feb;25(1):13-9. doi: 10.1089/cbr.2009.0673.
      2. Generation of a human anti-idiotypic antibody that mimics the GD2 antigen. Saleh MN, Stapleton JD, Khazaeli MB, LoBuglio AF. J Immunol. 1993 Sep 15;151(6):3390-8.
      3. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ. Cancer Biother Radiopharm. 1999 Dec;14(6):451-63
      4. EMERGE: A randomized Phase II study of the antibody-drug conjugate glembatumumab vedotin in advanced glycoprotein NMB-expressing breast cancer. Yardley DA, Weaver R, Melisko ME, Saleh MN, Arena FP, Forero A, Cigler T, Stopeck A, Citrin D, Oliff I, Bechhold R, Loutfi R, Garcia AA, Cruickshank S, Crowley E, Green J, Hawthrone T, Yellin MJ, Davis TA, Vahdat LT. J Clin Oncol. 2015 May; 33(14): 1609-19.

    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to view UAB Health System Provider Profile

  • Mollie deShazo 2014 smallRank: 
    Associate Professor 

    Division: 
    Hematology & Oncology

    Campus Address:
    NP 2576

    Mailing Address: 
    1720 2nd Avenue South, NP2540 
    Birmingham, AL 35294-3300

    Phone:
    (205) 996-7557

    Email:
    mdeshazo@uabmc.edu


    For an appointment, call(205) 934-9999 or toll free 1 (800) UAB-8816.

    Departmental Affiliation(s):
    Primary: Medicine

    Biosketch:

    Dr. deShazo sees patients with a variety of solid tumors and is especially interested in lung and genitourinary malignancies. She has taught medical students Introduction to Clinical Medicine for more than 5 years and was recently selected as one of ten faculty designated as Core Clinical Faculty for the Department of Internal Medicine Residency training program.

    Dr. deShazo is a member of the American Society of Clinical Oncology.

    Medical School:
    University of Alabama School of Medicine

    Internal Medicine Residency:
    University of Alabama at Birmingham

    Fellowship:
    Hematology/Oncology, University of Alabama at Birmingham

    Certifications:
    Board certified in Internal Medicine
    Board certified in Oncology


    Clinical Interests
    All malignancies, with focus in lung cancer and genitourinary cancers.


    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.

    Click to View UAB Health System Provider Profile

  • Nikolaos Papadantonakis 2017Rank:                  
    Assistant Professor

    Campus Address:
    NP 2540

    Mailing Address: 
    1720 2nd Avenue South, NP 2540
    Birmingham, AL 35294-3300

    Phone: 
    (205) 934-0916


    For an appointment,call (205) 934-9999 or toll free 1 (800) UAB-8816.

    Medical School:
    University of Crete Medical School, Crete, Greece

    Graduate School:
    PhD in Biochemistry and Medicine, University of Crete Medical School, Crete, Greece

    Internal Medicine Residency:
    Jacobi Medical Center / Albert Einstein College of Medicine, New York

    Fellowships:
    Hematology and Oncology Fellowship, Cleveland Clinic, Ohio

    Certifications:

    Board certified in Internal Medicine
    Board certified in Hematology
    Board certified in Medical Oncology



    Special Interests:

    Hematological Malignancies


    Publications: See a listing of publications on PubMed, a service of the National Library of Medicine.


    Click to view UAB Health System Provide Profile